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Abstract
Background: The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients
with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum
quantity with better safety profile than HS alone in patients with bronchiectasis.
Methods: In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA +7%HS; and 0.9%
isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration. Participants
inhaled each solution across four consecutive sessions. All sessions, except on session 3, also included 30 minutes of
airway clearance technique. A 7-day washout period was applied. Sputum weight was collected during the sessions
(primary outcome) aswell as during a 24-hour follow-up. The Leicester CoughQuestionnaire (LCQ) and lung function
were measured before/after each treatment arm. Safety was assessed by the monitoring of adverse events (AEs).
Results: Twenty-eight patientswith bronchiectasis (mean age of 64.0 (17.9) andFEV1%60.9 (24.6) of predicted)were
recruited. HS and HA+HS promoted similar expectoration during sessions, both being greater than IS [median
difference HS vs. IS 3.7 g (95% CI 0.5–6.9); HA+HS vs. IS 3.2 g (95%CI 0.5–5.9)]. Sputum expectorated exclusively
during theACTperiodwas similar across all treatment arms [HSvs. IS-0.3 g (95%CI-1.7 to 0.9);HA+HSvs. IS 0.0 g
(95%CI -1.3 to 1.4); HS vs. HA+HS 0.0 g (95%CI -1.2 to 0.4)]. Sputum collected over the 24-hour follow-up tended
to be lower forHS andHA+HS comparedwith IS [HS vs. IS -1.7 g (95%CI-4.2 to 0.0); HA+HSvs. IS-1.1 g (95%CI
-3.6 to 0.7)]. No differences in LCQ or lung function were observed. Most severe AEs were reported using HS.
Conclusion: HS and HA+HS were more effective on sputum expectoration than IS in patients with bronchi-
ectasis, reporting HA+HS better safety profile than HS.
Keywords: airway clearance techniques, bronchiectasis, hypertonic solutions, mucoactive treatment, sputum
expectoration
Introduction
According to the recent european guidelines, thehyperosmolar agents plus airway clearance techniques
(ACTs) may be considered to further enhance sputum expec-
toration in adult patients with noncystic fibrosis bronchiectasis
(henceforth referred to as ‘‘bronchiectasis’’(1)); however, sci-
entific evidence supporting this statement is quite scarce.(2)
The inhalation of hypertonic saline (HS) produces an
osmotic shock in the airway surface layer that improves
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airway hydration, accelerating mucus transportability.(3)
This effect of HS could potentiate and prolong the posterior
effectiveness of ACTs. Greater sputum weight has been
observed during combined sessions (inhalation and ACT)
using HS rather than isotonic solution (IS) in patients with
bronchiectasis and mild daily sputum expectoration (<10 g/
24 h).(4) However, the reasons why combined interventions
(rather than individual) could be more efficient are unclear.
Overall, short and long-term use of HS has been dem-
onstrated to be generally well tolerated by patients with
bronchiectasis(5) and other respiratory diseases.(6,7) Never-
theless, minor adverse events (AEs) (e.g., throat irritation,
excessive coughing, or airway narrowing) have been fre-
quently reported with HS inhalation.(8–10) These minor AEs
may appear after the first HS inhalation, negatively im-
pacting long-term treatment adherence.(9,11)
Hyaluronic acid (HA) is a glycosaminoglycan that is able
to mitigate bronchospasm induced by elastases and to bal-
ance water homeostasis in airways.(12,13) Therefore, the
addition of HA to HS (HA+HS) may be beneficial to im-
prove tolerance and efficacy of HS solution. Previous
studies conducted in cystic fibrosis showed greater tolerance
and pleasantness in favor of HA+HS compared with HS
alone.(8,11,14) So far, no studies have compared the effec-
tiveness and tolerability of HA+HS and HS in adult outpa-
tients with bronchiectasis. Improved tolerability with at least
equal efficacy of HA+HS may improve patients’ adherence,
while hopefully improving chronic respiratory symptoms
and quality of life (QoL) for patients with bronchiectasis.
Therefore, the purpose of this study was to evaluate
whether HA+HS is as efficacious as HS alone and better
than IS in improving sputum expectoration (primary out-
come), cough severity, and lung function in stable patients
with bronchiectasis and daily expectoration (>10 g/24 h)
naive to hyperosmolar agents. Also, this study aimed (i) to
examine whether hypertonic solutions (HS, HA+HS) could
increase effectiveness of ACTs in expectorated sputum
compared with IS; (ii) to analyze whether a combined ses-
sion of saline solutions and ACT is better than saline solu-
tions alone in enhancing sputum quantity; (iii) to evaluate
whether the short-term tolerability and safety of HA+HS is
better compared with HS alone.
Methods
Design
A double-blind, randomized, crossover trial with con-
cealed allocation was conducted. Participants each ran-
domly inhaled one of the three solutions: HS solution (7%
NaCl); HA + HS solution (0.1% sodium hyaluronate +7%
NaCl), and IS solution (0.9% NaCl), during four consecutive
sessions (once daily). A 7-day washout period was applied
between the treatment arms (Supplementary Fig. S1; Sup-
plementary Fig. S1; Supplementary Data are available on-
line at www.liebertpub.com/jamp).
A block random list was computer generated and retained
by a research nurse, not directly involved in the project. The
nurse received a notification email confirming the eligibility
criteria by the enrolling investigator and the randomization
took place after baseline data collection. Immediately, the
sequence of treatments was revealed to the pharmacist (also
external to the project) to produce the masking of inhaled
solutions. Patients and physiotherapists were thus blinded to
the inhaled solutions throughout the study.
The study was approved by the Hospital Clinic Research
Ethics Committee (HCP/2011/6401) and was performed in
accordance with the CONSORT statement (Clinical Trial
Registration Number NCT02392663). All participants gave
written informed consent before enrolment.
Participants
Patients were recruited from the Hospital Clinic, Barce-
lona, Spain. They were eligible to participate if over 18
years of age, diagnosed with bronchiectasis using high-
resolution computed tomography, clinically stable over the
previous 4 weeks,(15) producing spontaneous sputum ex-
pectoration (mean sputum ‡10 g/24 h), able to test the in-
halation solutions, and to perform the ACT. The exclusion
criteria included: smokers or former smokers (‡10-pack-
years),(16) bronchial hyperresponsiveness diagnosis,(17)
asthma(18) or allergic bronchopulmonary aspergillosis,(5)
forced expiratory volume in the first second (FEV1) <30%
after bronchodilation, total lung capacity <45%, and inha-
lation of mucoactive agents before screening.
Finally, the withdrawal criteria were: pulmonary exacer-
bation during the study or any new medical/personal con-
dition hindering study continuation.
Intervention
First, participants were encouraged to inhale 200 lg of
albuterol with a spacer chamber, or their usual bronchodi-
lator,(19) and before starting the inhalations they had to wait
15 minutes for short-acting bronchodilators or 30 minutes
for long-acting bronchodilators. Participants inhaled 5mL of
the assigned solution through a mouthpiece using a jet
nebulizer (PARI BOYSX device with PARI LC Sprint
nebulizer) in a seated position. They were instructed and
advised to inhale slowly and deeply follow by a short
breath-hold (2–3 seconds) to improve aerosol deposition.(20)
Participants stopped compressor during coughing and all
sessions were supervised by the physiotherapist to guarantee
the correct mode of breathing during the inhalation.
All sessions for all treatment arms included 30 minutes of
supervised ACT after inhalation, except for session 3. Au-
togenic drainage was the ACT chosen for the trial, based on
our previous experience in terms of patient preference and
short-term effectiveness(21) and was performed in a supine
position following the authors’ recommendations.(22,23)
Physiotherapist gave oral advice and manual feedback
during the performance. In each third session, participants
remained 30 minutes in the same supine position after the
inhalation period without performing any ACT (‘‘control
period’’).
Cough maneuvers were always spontaneous during ses-
sions, and if necessary pauses were allowed. Peripheral
oxygen saturation and heart rate were monitored during
intervention. All study visits were performed to the same
schedule at the hospital. Patients were asked not to perform
ACTs before the beginning of the sessions and for 24 hours
after the intervention.
Pharmacological treatments remained unchanged and
patients were encouraged to take their long-term medica-
tions at the same time of the day over the study period. All
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participants were trained to breathe with the glottis open and
coughing correctly before starting the trial.
Outcome measures
The primary outcome was the wet sputum expectoration
(g) collected during sessions. It was measured through two
preweighed containers, one to collect the sputum expecto-
rated during inhalation period and the other to measure the
sputum collected during ACT period. For the primary out-
come, session 3 (inhalation period + control period) was not
included, but the sputum expectorated was also measured
following the same procedure.
Secondary endpoints included the spontaneous sputum
expectorated over a 24-hour follow-up after the end of
sessions, collected in another preweighed container. The
timeline chosen for evaluating the long-lasting effects of
interventions was based on similar previous studies on
sputum expectoration.(21,24,25)
Secretions from sinus after an inspiratory forced maneu-
ver were not allowed to include in the containers. Partici-
pants were instructed to swallow saliva before coughing
during inhalation periods and also to avoid salivary con-
tamination over a 24-hour follow-up after intervention. In
addition, most part of possible saliva was removed from the
containers before weighing.
Cough severity, using the Leicester Cough Questionnaire
(LCQ)(26,27) and lung function (FEV1 and FVC),
(28) was also
assessed at the beginning and end of each treatment arm.At the
end of the trial, participants selected their preferred treatment
arm while also determining which solution was the saltiest.
Safety was assessed by monitoring AEs after each inha-
lation.(11) Perception of bronchospasm (wheezing or chest
tightness), excessive coughing, and throat irritation were re-
ported by participants and their severity was measured using
a three-point ordinal score(11) (0= absent, 1=mild, 2=mod-
erate, and 3= severe; from 0 to 9). The presence of hemop-
tysis and desaturation was assessed by the physiotherapist.
Tolerability was evaluated the first day of each saline
solution tested. A spirometry was performed pre- and
postbronchodilator and again 5 minutes after completing the
inhalation.(29) Participants with inhalation-induced bron-
chospasm (fall ‡12% FEV1)(30) were not allowed to con-
tinue the remainder sessions of the same treatment arm;
however, they continued the study trying the next saline
solution according to the same schedule and procedure.
Data analysis
A sample size of 20 completing patients was calculated to
be necessary to provide 80% power and 5% level of sig-
nificance, in a two-sided test, to detect a minimum 5.7 g(21)
of difference in sputum quantity during sessions, including
inhaled and ACT periods, between the three treatment arms.
This is based on the fact that the standard deviation of dif-
ference in the response variable for the same patient is
8.5.(21) Allowing for 20% early withdrawal, this study re-
cruited a total of 24 patients.
Repeated-measures analysis was performed using linear
mixed models to determine changes in expectorated sputum,
cough severity, lung function, and safety score across the
three treatment arms. Allocation sequence, group, and
treatment were considered as fixed effects, and subjects
within sequence were considered a random effect. The daily
expectoration measured before starting each treatment pe-
riod was incorporated into the model as a covariance (except
for safety analysis). Difference between the treatment arms
was reported as median difference (95% Confidence Interval
[CI])(31) and statistical significance was set at p< 0.05 for all
calculations.
All randomized participants were included in the analysis
for effectiveness (intention-to-treat basis); however, those
who never began treatment after the randomization process
(dropouts before the first session), did not complete the
study, or pass the tolerability test for all solutions, were not
included in the safety analysis.(32) Missing data were not
imputed.(33,34)
The sputum collected during the intervention and over the
24-hour follow-up was compared with a combined session,
including ACT period (session 1, 2, or 4), and the single
session, including a control period (session 3) using a
Wilcoxon test for each of the treatment arms. To select only
one of the three possible ACT sessions, a list of random
numbers was generated. The sputum obtained was analyzed
as sputum weight and sputum quantity ratio (%) (i.e., spu-
tum expectorated during the session or during the 24-hour
follow-up/total sputum collected · 100). Effect sizes were
computed to estimate the magnitude of changes, using rank-
biserial correlation (r) and interpreted as small effect (<0.3),
moderate effect (‡0.3), and large effect (‡ 0.5).
Results
From March to December 2015, thirty-eight volunteers
were screened for the study, with 28 meeting the eligibility
criteria, who were consented and randomized. Three par-
ticipants dropped out of the study before the first session and
two participants withdrew during the study (Supplementary
Fig. S2). Accordingly, 23 patients completed the study
protocol with 98% adherence to planned treatment sessions.
Participant characteristics are shown in Table 1. At the
beginning of all treatment arms, participants were similar
with respect to daily sputum expectoration, total LCQ score,
and lung function, indicating no carryover effects.
Treatment effect
Sputum expectoration. The primary outcome, sputum
collected during sessions (including inhalation plus ACT
periods) with HS and HA+HS treatments, was similar, both
being greater than that obtained with IS (Table 2).
Similarly, the sputum obtained exclusively during the
inhalation period was also similar to the HS and HA+HS
treatments, both being greater than that obtained with IS.
However, sputum expectorated exclusively during the ACT
period was similar across all treatment arms. The sputum
collected over the 24-hour follow-up showed a decreasing
trend from IS (the highest), to HA+HS and HS, being the
effects of hypertonic solutions being very similar (Table 2).
When comparing the random combined session, including
ACT (session 1, 2 or 4) and that without it (session 3), we
consistently observed more sputum in the combined session
at the end of sessions, independently of the inhaled solution
(Table 3). Consequently, the session sputum quantity ratio
(%) obtained was always greater for the combined session
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than session 3 [HS Inh+ACT vs. Inh+Control 14.5% (95%
CI 6.2–24.5); HA+HS Inh+ACT vs. Inh+Control 11.4%
(95% CI 2.2–20.3); IS Inh+ACT vs. Inh+Control 24.1%
(95% CI 11.1–35.9)] (Fig. 1).
On the contrary, the sputum quantity ratio obtained during
the 24-hour follow-up period was consistently proportionally
lower in the random combined session, including ACT
(session 1 or 2 or 4), than in session 3, including control
period for all solutions [HS Inh+ACT vs. Inh+Control
-11.6% (95% CI -22.9 to -3.2); HA+HS Inh+ACT vs. In-
h+Control -9.4% (95% CI -19.3 to -1.7); IS Inh+ACT vs.
Inh+Control -20.7% (95% CI -34.4 to -8.6)] (Fig. 1).
Finally, the time spent during inhalation period was similar
between the three solutions ( p= 0.06), showing greater
amounts of time spent with HS (20 minutes and 58 seconds)
and HA+HS (18 minutes and 39 seconds) treatments com-
pared with IS (16 minutes and 5 seconds) treatment.
Cough severity and lung function. By comparing the 3
treatments, the observed changes in total LCQ were not
significantly different ( p > 0.05). Lung function (FEV1 and
FVC) also remained unchanged after all interventions
( p > 0.05) (Supplementary Table S1).
Preference and salty taste. Around 48% of participants
who started all treatment arms selected HA+HS as their pre-
ferred solution to include in chronic treatment. As expected,
most of the patients (69%) reported HS as the saltiest solution.
Safety and tolerability of the intervention
HS showed the poorest safety profile [HS vs. IS 2.7 (1.6–
3.9); HS vs. HA+HS 1.2 (0.3–2.4)]; whereas HA+HS showed
an intermediate safety profile between HS and IS [HA+HS vs.
IS 1.2 (0.3–2.0)] (Supplementary Table S2). Coughing and
throat irritation were the most frequent minor AEs classified
as moderate or severe by participants, particularly after the
inhalation of HS and, to a lesser extent, after HA+HS (Fig. 2).
Mild oxygen desaturation was detected in three patients, but
the values increased to normal after the inhalation period.
Three small sputum samples stained with blood from two
participants (one during IS solution and the other during HS
and IS solution) were observed.
While IS solution was well tolerated by all participants,
the tolerability test of the HS solution failed in three pa-
tients. Two of these three patients also failed the tolerability
test for the HA+HS solution (Supplementary Fig. S2). These
three participants were elderly men (‡75 years) and pre-
sented a major impairment of lung function (FEV1 £ 40% of
predicted) compared with the sample average.
Consequently, the three treatment arms were completed
from 71% of randomized participants. Individually, 20
Table 1. Baseline Characteristics
of Randomized Participants
Characteristics (n = 28)
Age (yr), mean (SD) 64.0 (17.5)
Gender, n female (%) 18 (64.3)
BMI (kg/m2), mean (SD) 24.3 (3.6)
Etiology of bronchiectasis, n (%)
Unknown 10 (35.7)
Postinfection 12 (42.8)
Primary ciliary dyskinesia 3 (10.7)
Others 3 (10.7)
Chronic airway infection (%)a 22 (78.6)
P. aeruginosa infection 14 (50)
Lung function (FEV1)
Liters 1.5 (0.8)
% pred. 60.9 (24.6)
Long-term inhaled b2 agonists, n (%)
Short acting 3 (10.7)
Long acting 22 (76.6)
Long-term inhaled anticholinergics, n (%)
Short acting 2 (7.1)
Long acting 14 (50.0)
Long-term inhaled steroid therapy, n (%) 21 (75.0)
Long-term antibiotic treatment, n (%)
Oral (macrolides) 3 (10.7)
Inhaled 3 (10.7)
Baseline sputum expectorationb
24-hour period, median (IQR) 13.6 (10.8–21.4)
Data presented as n, n (%), mean (SD, standard deviation) and
median (IQR, interquartile range).
aChronic airway infection was defined as pathogen organism
cultured in at least two or more sputum samples, at least 3 months
apart, in the preceding 12 months.
bMeasured on two consecutive days during the week before the
start of the study.
BMI, body mass index; FEV1, forced expiratory volume in 1
second; FVC, forced vital capacity,% pred, percentage of predicted.
Table 2. Median (Interquartile Range) Values of Sputum Expectorated during Sessions 1, 2,
and 4 at Different Time Points for Each Treatment Arm and Median Difference (95% CI)
Between Treatment Arms
Treatment arms (n = 28) Median difference between treatment arms (n = 28)
HS HA + HS IS HS vs. HA + HS HS vs. IS HA + HS vs. IS
Inhalation + ACTa 11.3 (0.4–19.8) 10.7 (4.2–18.8) 8.4 (2.9–15.3) 0.4 (-0.4 to 2.2) 3.7 (0.5–6.9) 3.2 (0.5–5.9)
Inhalation 6.6 (0.4–11.2) 5.8 (0.9–11.1) 3.0 (0.9–5.2) 1.6 (0.0–2.8) 4.0 (1.6–6.7) 2.6 (1.3–4.6)
ACT 4.0 (0.0–7.8) 3.9 (1.3–9.6) 5.4 (1.7–8.4) 0.0 (-1.2 to 0.4) -0.3 (-1.7 to 0.9) 0.0 (-1.3 to 1.4)
24-hour follow-upb 4.8 (0.4–11.0) 7.7 (2.7–10.4) 8.4 (3.6–12.6) -0.2 (-2.2 to 1.4) -1.7 (-4.2 to 0.0) -1.1 (-3.6 to 0.7)
The amount of sputum was measured in grams (g).
aPrimary outcome.
bTwenty-four hour follow-up does not include the time of intervention. Comparisons were adjusted by the level of expectoration
collected before starting each treatment arm.
HS, hypertonic saline; HA + HS, hyaluronate acid plus hypertonic saline; IS, isotonic saline; ACT, airway clearance technique.
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(71%) patients completed the HS solution arm, 22 (79%) the
HA+HS solution arm, and 23 (82%) the IS solution arm.
Discussion
This is the first study to evaluate the impact of three
different saline solutions (HS, HA+HS, IS) inhaled before
ACT on sputum expectoration in adult outpatients with
bronchiectasis and chronic expectoration (>10 g/24 h).
The main findings were: (i) both hypertonic solutions at
7% (HS and HA+HS) promoted greater sputum weight
during sessions than IS. Contrarily, the sputum collected
over the 24-hour follow-up after sessions showed a de-
creasing trend from IS to HA+HS and, finally, to HS (the
lowest). No significant changes in cough severity and lung
function were observed between the treatment arms after
four sessions; (ii) effectiveness of ACT (using autogenic
drainage) seemed not to be influenced by the previously
inhaled solutions; in fact the sputum obtained during the
ACT period was similar throughout all treatment arms; (iii)
sputum collected at the end of a combined session (inhaled
+ ACT period) was always greater than a single session,
including the control period (session 3), independently of
the inhaled solution; conversely, the sputum expectorated in
the combined sessions 24 hours hence was clearly lower
than after session 3 (inhalation + control); (iv) globally, the
Table 3. Median (Interquartile Range) of Sputum Expectorated During the Random Combined
Session, Including ACT Period (Session 1 or 2 or 4) and the Single Session, Including Control
Period (Session 3) at the Different Periods for Each One of the Treatment Arms, Median
Difference (95% CI) Between the Sessions
Treatment arms (n= 28)
Median difference (95% CI)
Session including ACT vs. Session
including control period Effect size
Session including
ACT period
Session including
control period
HS
Inhalation + ACT/control 12.1 (0.5–21.8) 6.3 (0.0–11.7) 4.5 (2.1–9.7) 0.61
Inhalation 5.3 (0.5–12.7) 5.4 (0.2–9.4) 1.0 (0.0–3.0) 0.37
ACT/control 4.6 (0.0–7.5) 0.0 (0.0–2.0) 3.3 (1.8–5.4) 0.68
24-hour follow-upa 3.4 (0.0–12.7) 7.8 (0.0–19.7) -2.7 (-7.5 to -0.3) 0.57
HA + HS
Inhalation + ACT/control 11.5 (3.2–18.4) 6.2 (0.0–13.3) 4.0 (0.8–6.6) 0.52
Inhalation 6.3 (0.8–11.4) 4.5 (0.3–11.4) 0.0 (-2.0 to 2.3) 0.00
ACT/control 4.0 (0.8–8.7) 0.0 (0.0–1.9) 2.9 (1.7–5.3) 0.67
24-hours follow-upa 7.0 (1.6–12.5) 8.1 (2.3–18.9) -2.1 (-6.4 to -0.3) 0.53
IS
Inhalation + ACT/control 8.6 (3.4–13.7) 3.0 (0.0–4.7) 5.1 (3.5–8.4) 0.72
Inhalation 2.0 (0.1–4.6) 1.6 (0.0–3.5) 0.5 (-0.5 to 1.3) 0.16
ACT/control 5.7 (1.6–8.3) 0.5 (0.0–2.0) 4.4 (2.7–6.9) 0.76
24-hour follow-upa 6.0 (2.1–13.1) 10.0 (5.4–17.8) -1.9 (-6.6 to -0.1) 0.38
The amount of sputum was measured in grams (g).
aTwenty-four hour follow-up does not include the time of intervention.
FIG. 1. Percentage (%) of sputum clearance collected at different time points during
the random combined session (day 1 or 2 or 4), including ACT period and the single
session (session 3), including control period. ACT, airway clearance technique; HS,
hypertonic saline; HA+HS, hyaluronate acid plus hypertonic saline; IS, isotonic saline.
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solutions were well tolerated, but AEs during inhalation
were more frequent and severe, from HS to HA+HS to IS
(lowest).
The effect duration of hypertonic solutions (HS and
HA+HS) is poorly known in bronchiectasis, but their short-
term efficacy may be related to their improved biophysical
sputum properties (lower adhesivity and greater cough
transportability)(35,36) The major short-term efficacy of hy-
pertonic solutions was also confirmed by the lower sputum
expectoration observed in the 24 hours following HS and
HA+HS, compared with IS. Hypertonic solutions were able
to concentrate greater amounts of sputum during the treat-
ment period and reduce the need to expectorate throughout
the rest of the day, being one of the main short-term goals of
airway clearance treatment.(37) A similar finding was de-
scribed during the 24-hour period following the intervention
in a previous trial comparing different ACTs in patients with
bronchiectasis.(21)
However, this result should be taken with caution because
the measure of sputum expectoration has some potential
limitations (saliva contamination, involuntary swallowing,
patient compliance) and does not necessarily reflect the
impact on airway clearance.
Kellet et al.(4) did not clearly describe whether the in-
creased sputum weight obtained using HS compared with IS
was due to the osmolality of the different solutions or to the
increased effectiveness of ACT after the inhalation of HS in
patients with bronchiectasis and mild daily sputum expec-
toration (<10 g/24 h). In our study, no increased effective-
ness during ACT was observed following hypertonic
solutions, despite their higher osmotic impact on the airway
surface layer compared with IS. Baseline sputum expecto-
ration in our population (>10 g/24 h) was greater compared
with Kellet’ study, thus proving to be irrelevant to the ef-
ficacy of hyperosmolar solutions. Moreover, our findings
confirm that the advantage of HS and HA+HS on sputum
expectoration is more related to the inhalation than to ACT.
Unfortunately, the study design did not have a single
ACT arm (no previous inhalations) that would have helped
to better understand the interaction between inhalations and
the efficacy of ACT. Thus, future studies are recommended
to further investigate if the efficacy of ACTs is influenced by
previous saline solutions in bronchiectasis.
Similarly, inhalation of HA alone was not evaluated in the
present study. Previous studies suggest that inhalation of HA
reduces elastin degradation in COPD and prevents bronch-
oconstriction in people with asthma without AEs re-
ported.(13,38,39) To the authors’ best knowledge, inhalation
of HA alone has never been explored in bronchiectasis and
further research is needed to evaluate the impact of this
treatment on mucus clearance and airway inflammation.
Participants used bronchodilators before all inhalations to
improve tolerability,(2) optimize pulmonary deposition,(2) and
improve cough clearance of secretions by increasing expira-
tory flow.(40) It is known that b-agonist bronchodilators may
stimulate ciliary beat frequency and anticholinergics can de-
crease volume of secretions that is triggered by airway in-
flammation.(41) In this study, participants were clinically
stable throughout the study, their medication was unchanged,
and the study design allowed intrasubject comparison,(42)
therefore the impact of bronchodilators on sputum expecto-
ration differences between treatment arms is limited.
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The length of combined sessions (inhalation + ACT pe-
riod) may be considered burdensome by patients. Con-
sidering our results, it might be recommended to include an
ACT after inhalation to achieve a greater reduction of daily
expectoration after intervention, independently of the solu-
tion previously inhaled. Studies conducted in patients with
cystic fibrosis suggest that the timing of HS (before or
during ACTs) had no impact on the clinical effective-
ness,(43,44) although it clearly reduces the time burden as-
sociated with treatment and may promote future adherence.
Future studies are required to explore if HS and HA+HS
inhalation during ACT has similar results in patients with
bronchiectasis as well as an equal reduction in the need for
expectoration after the intervention.
Previous studies comparing the effects of HS and IS on
QoL and lung function have demonstrated controversial
findings.(5) No significant changes were observed in LCQ
score and lung function across all treatment arms. Perhaps
the short duration of our intervention did not enable us to
observe a significant impact on the LCQ, a subjective as-
sessment of cough. Thus, future studies may incorporate
cough monitoring to detect objectively differences in cough
frequency between interventions.(45)
Furthermore, it has been hypothesized that the response to
hypertonic saline could increase with the severity of lung
function impairment.(3) Therefore, it is likely that greater
changes in cough severity and lung function could be ex-
pected in patients with more severe bronchiectasis and lung
function impairment, unlike our population which showed a
moderate lung obstruction (FEV1 = 61% of predicted).
Globally, the saline solutions were well tolerated. The
participants that did not pass the tolerability test for hy-
pertonic solutions were elderly with severe lung obstruction.
As expected, the main AEs reported were with HS, whereas
HA+HS showed an improved safety profile, between those
of HS and IS. These findings agree with previous studies
conducted within cystic fibrosis,(8,11,14) and support the al-
ternative use of HA+HS in bronchiectasis. The relatively
low rate of AEs of HA+HS may also explain why it was
chosen as the preferred saline solution by patients.
The present study has different strengths: despite the
weighing wet sputum being controversial as an outcome
measure(46) and only can be interpretable over a short-effect
period,(37) the crossover study design with consecutive ses-
sions improved the accuracy of our results, allowing in-
trasubject comparisons.(42) The repeated measurements of
sputum at different points in time (inhalation, ACT, and
24 hours follow-up) also better describe immediate and short-
term effects on sputum expectoration, such as frequency and
severity of the AEs of the different saline solutions in patients
with bronchiectasis. For future long-term trials, mucus de-
hydration (e.g., sputum percentage solids) or sputum in-
flammatory cells may be a useful measurement to assess the
effect of hypertonic saline solutions on disease severity.
The main limitation was that most participants identified
the HS solution by its salty taste; however, HA+HS and IS
were not easily identifiable. It was decided not to use qui-
nine sulfate as a blinding agent, as it is unknown whether it
may influence the HA+HS properties and alter its effec-
tiveness. However, our participants were naive to inhaled
saline solutions and not informed about the different char-
acteristics of the three treatment arms. A similar limitation
was observed in the Nicolson et al.(47) study, demonstrating
that salty taste does not consistently affect the blindness of
participants.
Finally, the high dropout rate throughout the study may
be another limitation. Nevertheless, the primary reason for
withdrawal was related to the time burden perceived by
participants. Although the research protocol could have been
easily performed at home, we preferred the hospital setting
to guarantee a close monitoring of AEs.
In conclusion, we found that inhaled HA+HS was as ef-
ficacious as HS in improving sputum expectoration, but with
a better safety profile in patients with bronchiectasis.
Moreover, the additional performance of ACT (autogenic
drainage) after hypertonic solutions achieved the greater
sputum weight, and a significant reduction in expectoration
for the rest of the day. The daily use of hypertonic saline
solutions, combined with ACT, may be useful in reducing
the burden of daily symptoms, although further investigation
is needed to assess long-term outcomes.
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